Recent publications document an exponential increase in the use of dominant-negative mutations as tools for the experimental dissection of lymphocyte signaling pathways. This approach may be the only one available for in vitro analysis of cell lines. Moreover, when implemented in transgenic animals, dominant-negative mutations boast certain advantages over gene-targeting strategies.